Erectile Dysfunction
Conditions
Keywords
Vardenafil, Erectile dysfunction, Phosphodiesterase Inhibitors, Combination use with alpha-blockers
Brief summary
Main object is to investigate the safety profile of Levitra in combination use with alpha-blockers in patients with erectile dysfunction used in clinical practice after launch. In the initial combination date and the first and second observation after initial combination date, number of tablets prescribed, dose of tablets and number of tablets taken until follow-up visit will be investigated. The efficacy and tolerability will be evaluated at 2 months after initial combination date.
Interventions
Patients under daily life treatment receiving Levitra according to local drug information.
Sponsors
Bayer
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients \>/= 18 years * Enrollment within 7 days after initiation of combination use of Levitra and alpha-blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of Levitra treatment, namely satisfactory or not is evaluated by inquiring to the enrolled patient according to the following rating scale: 1.very satisfied, 2.satisfied, 3.unsatisfied | 2 months |
| Safety of Levitra treatment, namely incidence of Adverse Events or Adverse Drug Reactions are evaluated | 2 months |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability of patients with Levitra treatment, namely satisfactory or not is evaluated by inquiring to the enrolled patient according to the following rating scale: 1.very satisfied, 2.satisfied, 3.unsatisfied | 2 months |
Countries
Japan
Outcome results
None listed